Regeneron and Sanofi expand alliance to add four long‑acting immunology antibodies
Regeneron and Sanofi announced an expansion of their long‑standing antibody partnership to co‑develop and co‑commercialize four new long‑acting antibodies targeting IL‑13, an IL‑4xIL‑13 bispecific, IL‑4 and IL‑4Rα. Regeneron will receive a $1 billion upfront payment and may earn up to $7 billion in milestone payments, with development costs and future profits split 50:50. The companies will share R&D leadership (Regeneron) and global commercialization (Sanofi) and have settled prior collaboration‑related litigation.
Why it matters
The upfront cash and potential milestones provide Regeneron with significant near‑term funding and upside, while Sanofi gains access to new pipeline assets that could broaden its immunology franchise. The 50:50 cost and profit sharing means both firms will benefit proportionally from any future product success.
Key facts
- 1Regeneron will receive an upfront payment of $1 billion from Sanofi. globenewswire.com
- 2Regeneron may receive up to $7 billion in additional milestone payments. globenewswire.com
- 3The expanded agreement adds four new long‑acting antibodies invented by Regeneron. globenewswire.com
- 4REGN20423 is in a Phase 1 trial for atopic dermatitis; the other three antibodies are slated for clinical studies in 2027. marketscreener.com
- 5Regeneron will lead research and development; Sanofi will lead global commercialization. marketscreener.com
- 6The companies will share development and commercialization costs and split future profits equally on a global basis. marketscreener.com
Summary written by AlphAI from 9 of 9 sources. Not investment advice. Figures are as stated by the linked sources.